Expertise in
4
conditions

Dr. Brandon J. Essink

Family Medicine
Montgomery County Memorial Hospital
2301 Eastern Ave, 
Red Oak, IA 
Accepting New Patients
Expertise in
4
conditions
Montgomery County Memorial Hospital
2301 Eastern Ave, 
Red Oak, IA 

Overview

Brandon Essink is a primary care provider, practicing in Family Medicine in Red Oak, Iowa.

Dr. Essink is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Flu, Parainfluenza, Severe Acute Respiratory Syndrome (SARS), and Parainfluenza Virus Type 3.

He is actively involved in clinical research, co-authoring 52 peer reviewed articles and participating in 9 clinical trials. Dr. Essink is currently accepting new patients.

Specialties

Family Medicine

Licenses

Family Medicine in NE

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 6 Less Insurance Carriers -

Locations

Montgomery County Memorial Hospital
2301 Eastern Ave, Red Oak, IA 51566
Other Locations
Meridian Clinical Research LLC
3319 N 107th St, Omaha, NE 68134

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3, Randomized, Double-blind, Parallel-group Trial to Evaluate the Lot Consistency, Immunogenicity, and Safety of AV7909 for Postexposure Prophylaxis of Anthrax in Healthy Adults
A Phase 3, Randomized, Double-blind, Parallel-group Trial to Evaluate the Lot Consistency, Immunogenicity, and Safety of AV7909 for Postexposure Prophylaxis of Anthrax in Healthy Adults
Enrollment Status: Completed
Publish Date: May 06, 2026
Intervention Type: Biological
Study Phase: Phase 3
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
Enrollment Status: Completed
Publish Date: July 31, 2025
Intervention Type: Biological
Study Drug: RSVPreF3
Study Phase: Phase 3
A Phase II, Observer-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of a Varicella Vaccine at Various Potencies Compared With Varivax, as a First Dose, Administered in Healthy Children in Their Second Year of Life
A Phase II, Observer-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of a Varicella Vaccine at Various Potencies Compared With Varivax, as a First Dose, Administered in Healthy Children in Their Second Year of Life
Enrollment Status: Completed
Publish Date: February 28, 2025
Intervention Type: Biological
Study Phase: Phase 2
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Biological, Other
Study Drug: SARS-CoV-2 rS/Matrix-M1 Adjuvant
Study Phase: Phase 3
Phase I/II, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Respiratory Syncytial Virus (RSV) Vaccine GSK3844766A in Subjects Aged 18-40 or 60-80 Years
Phase I/II, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Respiratory Syncytial Virus (RSV) Vaccine GSK3844766A in Subjects Aged 18-40 or 60-80 Years
Enrollment Status: Completed
Publish Date: August 05, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
A Phase 2b, Open-label, Multi-center, Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 Older Adults (OA) Investigational Vaccine Administered Intramuscularly 18 Months Post-Dose 2 in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study
A Phase 2b, Open-label, Multi-center, Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 Older Adults (OA) Investigational Vaccine Administered Intramuscularly 18 Months Post-Dose 2 in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study
Enrollment Status: Completed
Publish Date: June 29, 2022
Intervention Type: Biological
Study Drug: RSVPreF3 OA investigational vaccine
Study Phase: Phase 2
A Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Phase 1b Study to Evaluate the Safety and Immunogenicity of an Intranasal Live Attenuated Respiratory Syncytial Virus (RSV) Vaccine in Seropositive Young Children
A Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Phase 1b Study to Evaluate the Safety and Immunogenicity of an Intranasal Live Attenuated Respiratory Syncytial Virus (RSV) Vaccine in Seropositive Young Children
Enrollment Status: Completed
Publish Date: June 29, 2021
Intervention Type: Other, Biological
Study Phase: Phase 1
12 Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From A Major Depressive Disorder (MDD) Having Had- Within the Current Episode- An Inadequate Response to at Least One Medication Included in GeneSight Psychotropic
12 Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From A Major Depressive Disorder (MDD) Having Had- Within the Current Episode- An Inadequate Response to at Least One Medication Included in GeneSight Psychotropic
Enrollment Status: Completed
Publish Date: January 14, 2020
Intervention Type: Genetic
Study Phase: Not Applicable
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 8 Less Clinical Trials

52 Total Publications

Immunogenicity and Safety of vYF, a Yellow Fever Vaccine - A Phase 2 Trial.
Immunogenicity and Safety of vYF, a Yellow Fever Vaccine - A Phase 2 Trial.
Journal: The New England journal of medicine
Published: April 08, 2026
Similar Doctors
Expertise in
12
conditions
Dr. Warren C. Hayes
Family Medicine
Expertise in
12
conditions
Dr. Warren C. Hayes
Family Medicine

Montgomery County Memorial Hospital

2301 Eastern Ave, 
Red Oak, IA 
 (0.1 miles away)
712-527-3245
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Warren Hayes is a primary care provider, practicing in Family Medicine in Red Oak, Iowa. Dr. Hayes is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Hypothyroidism, Lung Metastases, Lung Cancer, and Maturity Onset Diabetes of the Young. Dr. Hayes is currently accepting new patients.

Expertise in
17
conditions
Dr. James T. Biskup
Family Medicine
Expertise in
17
conditions
Dr. James T. Biskup
Family Medicine

Bellevue Family Practice PC

2206 Longo Dr, Suite 201, 
Bellevue, NE 
 (37.9 miles away)
402-292-0114
Languages Spoken:
English
See accepted insurances
Accepting New Patients

James Biskup is a primary care provider, practicing in Family Medicine in Bellevue, Nebraska. Dr. Biskup is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Hypogonadism Primary Partial Alopecia, Male Pseudohermaphroditism with Gynecomastia, Eunuchoidism Familial Hypogonadotropic, and Testicular Failure. Dr. Biskup is currently accepting new patients.

Expertise in
14
conditions
Dr. Janet M. Reuter
Family Medicine
Expertise in
14
conditions
Dr. Janet M. Reuter
Family Medicine

Office

1001 Risen Son Blvd, 
Council Bluffs, IA 
 (33.5 miles away)
712-256-8600
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Janet Reuter is a primary care provider, practicing in Family Medicine in Council Bluffs, Iowa. Dr. Reuter is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses PMM2-Congenital Disorder of Glycosylation, Sialuria, Phosphomannoisomerase Deficiency, and Sialic Acid Storage Disease. Dr. Reuter is currently accepting new patients.

Frequently Asked Questions about Dr. Brandon J. Essink

How do I make an appointment with Dr. Brandon J. Essink?

You can book an appointment with Dr. Brandon J. Essink by calling their office at 712-623-7000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Brandon J. Essink a top-rated expert for Flu?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Brandon J. Essink is classified as an Advanced expert for Flu, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Brandon J. Essink specialize in?

While Dr. Brandon J. Essink is a Family Medicine, they have specific expertise in Flu, Parainfluenza, and Severe Acute Respiratory Syndrome (SARS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Family Medicine.

Does Dr. Brandon J. Essink participate in research or clinical trials?

Yes. Dr. Brandon J. Essink has published 52 articles and abstracts on conditions like Flu. You can view a list of Dr. Brandon J. Essink's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Brandon J. Essink accept my insurance?

Dr. Brandon J. Essink accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 712-623-7000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Essink's expertise for a condition
ConditionClose
      View All 13 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile